Treatment of diabetes mellitus type 2 patients with the long-acting insulin analogue, glargine, was found to be associated with an increased incidence of all cancers compared to natural therapeutic insulin in two studies [176, 177] and in pancreatic and colorectal cancer in a third study [178] whereas in a fourth study the increased risk for breast cancer was equal to unmodified insulin [179]. The gene discussed is INS; the disease is type 2 diabetes mellitus.